Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
EXELthis companyExelixis, Inc.	$70.08	15.13×	5.48×	5.1×	12.5×	124.2%	96.4%	37.6%	33.7%	36.2%	29.7%	7.1%	0.08×	-0.34×	0×	3.56×	0.0%	6	18.06	4	A
CRISCuris, Inc.	$0.75	-1.7×	2.38×	1.38×	-1.83×	-1429.1%	99.5%	-348.4%	-80.3%	-138.8%	-464.7%	-209.4%	0.3×	0.66×	-15.06×	0.49×	0.0%	0	-98.45	1	C-
INCYIncyte Corporation	$120.30	14.99×	3.73×	3.75×	9.23×	-2.4%	92.8%	26.1%	25.0%	24.9%	20.6%	7.0%	0.01×	-1.72×	553.04×	3.32×	0.0%	6	10.87	3	B+
RIGLRigel Pharmaceuticals, Inc.	$41.79	2.1×	1.97×	2.62×	5.95×	-171.8%	93.3%	42.6%	124.7%	93.8%	28.2%	9.8%	0.14×	0.1×	17.14×	2.42×	0.0%	4	4.57	4	A
RVMDRevolution Medicines, Inc.	$199.41	-13.39×	9.28×	0×	-13.68×	-99.5%	0.0%	0.0%	0.0%	-69.3%	-56.8%	-6.0%	0.1×	0.21×	-48.8×	7.14×	0.0%	1	12.52	1	C-
SNDXSyndax Pharmaceuticals, Inc.	$9.40	-6.39×	28.16×	10.56×	-8.07×	-0.0%	96.0%	-158.4%	-165.6%	-441.6%	-66.6%	-17.8%	5.36×	-0.84×	-8.08×	4.4×	0.0%	3	-1.72	1	D+
Peer median	—	-1.7×	3.73×	2.62×	-1.83×	-99.5%	93.3%	0.0%	0.0%	-69.3%	-56.8%	-6.0%	0.14×	0.1×	-8.08×	3.32×	0.0%	3	4.57	1	—